ClinicalTrials.gg
RecruitingNCT06722196BEAT-AFUpdated Dec 9, 2025

BiodEgradable Soaked Amiodarone paTch Use for the Prevention of Atrial Fibrillation After Cardiac Surgery

A Phase 3 interventional study of topical amiodarone and saline solution patch in Atrial Fibrillation (AF), sponsored by Jilin Heart Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by Jilin Heart Hospital · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 377 studies in Atrial Fibrillation with a site in China — 162 open to participants now, 183 under way, 4 of them phase 3. Atrial Fibrillation · China.

Planned enrollment
71st of 256
500 · median 235
Started
2025
with 54 others
Phase 3
20 of 377
3 open now
Primary completion
2027-01
later than 95 of 182 live
Registered
260th of 377
by date

Among the 377 studies in Atrial Fibrillation with a site in China, this one is the 71st largest by planned enrollment of the 256 interventional ones that give a count, is one of 55 that started in 2025, is one of 20 in phase 3, reaches primary completion later than 95 of the 182 other live ones, and was the 260th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

162 of the 377 studies in Atrial Fibrillation with a site in China are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Atrial Fibrillation with a site in China, or all of them as a file.
02

Study summary

The primary objective of the present prospective, randomized, double blind, controlled study is to assess whether the application of 2 oxidized regenerated cellulose (SurgicelTM FibrillarTM) patches soaked with amiodarone hydrochloride over the anterior wall of the left atrium and the lateral wall of the right atrium results in a reduction in the incidence of POAF

03

Conditions studied

  • Atrial Fibrillation (AF)

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients who are candidates for elective cardiac surgery trough complete sternotomy with indications of coronary artery disease (both off-pump and on-pump), aortic valve disease, mitral valve disease, tricuspid valve disease, and ascending aorta disease, whether as an isolated pathology or in combination

Exclusion criteria

Exclusion Criteria:

  • patients with a clinical history of atrial or ventricular arrhythmia of any nature and duration, patients undergoing reoperation, patients with emergency surgical indications due to acute myocardial infarction or cardiogenic shock, patients with thyroid disfunction, patients with HOCM and those with pacemakers or ICDs
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Experimental

    patients will receive 2 patches soaked in cordarone hydrochloride (150 mg/3 ml each)

  • Sham comparator
    Sham

    patients will receive 2 patches soaked in saline solution (3 ml each)

Interventions

  • DrugAmiodaroneStudies of AmiodaroneAmiodarone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    amiodarone soaked patch placed on the left atrial roof at the end of surgery

  • Othersaline solution patch

    saline solution soaked patch placed on left atrial roof at the end of surgery

06

What researchers measure

Primary outcomes

  1. postoperative atrial fibrillation versus control

    incidence of in-hospital atrial fibrillation

    Time frame: within 5 days after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jan 2027, 23 months after the start.

Of 62 non-industry phase 3 interventional studies under Atrial Fibrillation, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 73. This study's planned 23 months is below that.

Counting every sponsor, half of 83 studies reached it within 42 months; a quarter within 32 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2024
First posted
Dec 9, 2024
StartActual
Feb 15, 2025
Primary completionEst.
Jan 15, 2027
CompletionEst.
Dec 15, 2027
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06722196
Lead sponsor
Jilin Heart Hospital
Collaborators
Cornell University
Responsible party
Sponsor
First posted
Dec 9, 2024
Start date
Feb 15, 2025
Primary completion
Jan 15, 2027 (estimated)
Completion
Dec 15, 2027 (estimated)
Last update
Dec 9, 2025

Study contacts

Xin Lu
Contact
xin.lu@jlheart.org
+86 13630550809
Sui C Yu
Contact
chunyu.sui@jlheart.org
+86 17304316969
Massimo G Lemma, PhD
principal investigator · Jilin Heart Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion